This product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 cell line, harboring targeted disruption of the DTD1 gene. The heterogeneous pool of cells provides a loss-of-function model for studying D-aminoacyl-tRNA hydrolase 1 (DTD1) in human cells. This polyclonal format captures a range of editing events, enabling downstream functional analyses without clonal selection. The knockout model is designed for research use in translation fidelity, amino acid metabolism, and protein quality control investigations.
The HAP1 cell line is a near-haploid, fibroblast-like line originally derived from the KBM-7 chronic myeloid leukemia (CML) cell line, which is BCR-ABL positive. Its haploid nature simplifies genetic manipulation and facilitates genome-wide knockout screens and functional genomics studies. HAP1 cells maintain key eukaryotic pathways, making them a robust model for studying cellular processes relevant to cancer biology and beyond. The cells are adherent and exhibit consistent growth characteristics, supporting reproducible experimental setups.
DTD1 is a critical enzyme that hydrolyzes D-aminoacyl-tRNAs, preventing misincorporation of D-amino acids into nascent polypeptides during translation. This proofreading function is essential for maintaining translation fidelity and proteome integrity. DTD1 is thought to be regulated by mTOR signaling and amino acid availability, acting downstream of these inputs to intercept D-aminoacyl-tRNAs at the ribosome. It directly interacts with D-aminoacyl-tRNA substrates and potentially with ribosomal proteins, blocking their utilization by elongation factor EF-Tu. When DTD1 activity is lost, D-amino acids are erroneously incorporated, leading to misfolding, aggregation, and proteotoxic stress, which in turn engages the proteostasis network including the proteasome for clearance.
In the HAP1 cellular context, DTD1 knockout provides a valuable system to dissect the consequences of D-amino acid misincorporation. The near-haploid background reduces genetic redundancy, accentuating phenotypic effects. This model is particularly suited to exploring how proteotoxic stress contributes to cancer and neurodegenerative disorders, where aberrant protein aggregation is a hallmark. The loss of DTD1 in these BCR-ABL-positive cells may also reveal vulnerabilities related to translational control and stress response pathways.
Functional applications include large-scale genetic interaction screens to identify modulators of D-amino acid sensitivity, mechanistic studies of translation fidelity, and drug target validation for therapies aimed at proteostasis. Representative assays include Western blotting to confirm DTD1 loss, RT-qPCR for transcript analysis, tRNA charging assays to measure D-aminoacyl-tRNA levels, puromycin incorporation assays to assess translation rates, growth assays under D-amino acid stress, and mass spectrometry to detect D-amino acid-containing peptides. For further details, please contact Ascent Research.
